Tagged with M

Singapore As the most important pharma hub in its region, and one of the most important globally, many companies look to launch new products in Singapore first before expanding to other markets. This situation keeps the Health Sciences Authority (HSA) – the country’s regulatory body – extremely busy. While challenges, including…

Saudi Arabia A rundown of five things to know about the USD 8.2 billion Saudi pharma market, including the impact of ‘Vision 2030’, the country’s leading position in the MENA region, why halal pharmaceuticals are not to be ignored, the regional firms playing among global giants in the Kingdom, and leading therapeutic…

China One of the largest domestic pharma companies in China (ranking number one from 2014 to 2019), Yangtze River Pharmaceutical Group (YRPG) is so-named for its location in Taizhou, Jiangsu Province, part of the Yangtze River Delta, where the Yangtze River feeds into the East China Sea. Founded initially in 1971,…

Switzerland Lorenzo Ambrosini of the Agire Foundation introduces the major new innovation projects underway in the Italian-speaking Swiss canton of Ticino; the canton’s strong existing footprint in bioinformatics, AI, and computer modelling; and how it is looking to leverage its connections to the rest of Switzerland and to Italy.   A…

Asia-Pacific At USD 150 billion, Asia-Pacific is home to the world’s second largest medtech market and, with a CAGR of nine percent, certainly its most dynamic. Chronic underfunding of healthcare systems in APAC means that a region accounting for 60 percent of the world’s population only represents a quarter of global…

MEA The latest news from Middle East & North African pharma, including Pfizer’s transformation of its Saudi operations; why India is calling for reform of the import process for pharma products in the Arab world; Hikma’s buyup of GSK assets in Egypt and Tunisia; and Tabuk’s biosimilar distribution deal.   Pfizer…

China The Chinese NMPA’s drug approval list for 2020 includes a surge in approvals for locally developed drugs. A total of 46 new drugs were approved in 2020 (less than the 53 approved in 2019), including 28 chemical drugs and 18 biological products. Read more analysis from Xu Wang of Novo…

Switzerland Switzerland is a crucial country for MSD’s global network, employing over 1000 people in local, regional, and global functions across four sites in Lucerne and a newly opened site in Zurich specialising in R&D, data management, and commercialisation. With 25 ongoing clinical trials per year, Switzerland is an important country…

Global As the global pharmaceutical industry continues to grow, so have opportunities for service providers. Over the last few decades, while big pharma companies continued to focus on their core business, contract development and manufacturing organizations (CDMOs) have positioned themselves as alternatives to in-house development and manufacturing operations, promising to decrease…

Germany After a year of growth and acquisitions, 125-year-old German generics manufacturer STADA is showing a willingness to make bold bets on areas including consumer healthcare, medical cannabis, and research into public opinion on healthcare   STADA, based in Bad Vilbel, focuses on a two-pillar strategy consisting of generics, including specialty…

USA The AAM’s Dan Leonard highlights the savings impact that generic and biosimilar medicines have on US healthcare today and introduces the ‘Secure Our Meds’ campaign which aims to educate policymakers on the importance of generic and biosimilar market competition and how it can be safeguarded.   More than 35 years…

Singapore Lance Little, managing director for Roche Diagnostics in Asia Pacific and board member of the Asia Pacific Medical Technology Association (APACMed), shares how COVID has affected their business in the region, his changing priorities during these challenging times, and the importance of building a unified culture across the regional organization,…